IL81964A - Aprotinin and aprotinin homologues in which the amino acids in positions 15 and 52 have benn substituted - Google Patents

Aprotinin and aprotinin homologues in which the amino acids in positions 15 and 52 have benn substituted

Info

Publication number
IL81964A
IL81964A IL81964A IL8196487A IL81964A IL 81964 A IL81964 A IL 81964A IL 81964 A IL81964 A IL 81964A IL 8196487 A IL8196487 A IL 8196487A IL 81964 A IL81964 A IL 81964A
Authority
IL
Israel
Prior art keywords
aprotinin
benn
substituted
positions
amino acids
Prior art date
Application number
IL81964A
Other languages
English (en)
Other versions
IL81964A0 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL81964A0 publication Critical patent/IL81964A0/xx
Publication of IL81964A publication Critical patent/IL81964A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL81964A 1986-03-26 1987-03-23 Aprotinin and aprotinin homologues in which the amino acids in positions 15 and 52 have benn substituted IL81964A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08607523A GB2188322A (en) 1986-03-26 1986-03-26 Aprotinin and analogues thereof produced by a recombinant host

Publications (2)

Publication Number Publication Date
IL81964A0 IL81964A0 (en) 1987-10-20
IL81964A true IL81964A (en) 1993-07-08

Family

ID=10595278

Family Applications (1)

Application Number Title Priority Date Filing Date
IL81964A IL81964A (en) 1986-03-26 1987-03-23 Aprotinin and aprotinin homologues in which the amino acids in positions 15 and 52 have benn substituted

Country Status (15)

Country Link
US (1) US4894436A (fi)
EP (1) EP0238993B1 (fi)
JP (1) JP2537507B2 (fi)
KR (2) KR950000302B1 (fi)
CN (1) CN1018793B (fi)
AT (1) ATE123301T1 (fi)
AU (1) AU600475B2 (fi)
CA (1) CA1338309C (fi)
DE (1) DE3751324D1 (fi)
DK (1) DK151687A (fi)
ES (1) ES2073390T3 (fi)
FI (1) FI94876C (fi)
GB (1) GB2188322A (fi)
IL (1) IL81964A (fi)
ZA (1) ZA872181B (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188933A (en) * 1986-04-10 1987-10-14 Bayer Ag Expression vectors for production of polypeptides, method for enhanced expression of polypeptides, hosts containing the expression vectors, products manufactured thereby
US5654176A (en) * 1987-05-28 1997-08-05 Amrad Corporation Limited Fusion proteins containing glutathione-s-transferase
DE3724570A1 (de) * 1987-06-27 1989-01-05 Bayer Ag Human-aprotinin, dessen lys-rest in position 15 gegen einen anderen protogenen aminosaeurerest ausgetauscht ist
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
ES2063161T3 (es) * 1988-03-07 1995-01-01 Ciba Geigy Ag Proteinas modificadas.
US5180667A (en) * 1988-03-07 1993-01-19 Ciba-Geigy Corporation Genes encoding eglin C mutants
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5231010A (en) * 1989-09-13 1993-07-27 Bayer Aktiengesellschaft Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof
DE3930522A1 (de) * 1989-09-13 1991-03-21 Bayer Ag Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben
AU8740491A (en) * 1990-09-28 1992-04-28 Protein Engineering Corporation Proteinaceous anti-dental plaque agents
IL99585A0 (en) * 1990-10-01 1992-08-18 Novo Nordisk As Aprotinin analogues,their production and pharmaceutical compositions containing them
EP0486001A1 (en) * 1990-11-13 1992-05-20 Mochida Pharmaceutical Co., Ltd. Recombinant urinary trypsin inhibitor fragments and drug composition
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
DE69230061T2 (de) * 1991-07-25 2000-01-05 Oriental Yeast Co. Ltd., Tokio/Tokyo Künstliches immunoglobulin-bindendes protein
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5824870A (en) * 1995-11-06 1998-10-20 Baszczynski; Chris Commercial production of aprotinin in plants
ATE290878T1 (de) * 1996-12-06 2005-04-15 Fonden Til Fremme Af Eksperime Inhibierung von invasiver remodulierung
FR2774988B1 (fr) * 1998-02-16 2000-05-05 Commissariat Energie Atomique Procede de purification de la prpres a partir d'un echantillon biologique et ses applications
US7241730B2 (en) * 1998-08-27 2007-07-10 Universitat Zurich Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
US7432238B2 (en) * 2004-04-16 2008-10-07 Stc.Unm Human Kunitz-type inhibitor with enhanced antifibrinolytic activity
US7910550B2 (en) * 2004-04-16 2011-03-22 Stc.Unm Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US20060218667A1 (en) * 2004-10-12 2006-09-28 Vojdani Fakhrieh S Plant-produced recombinant aprotinin and aprotinin variants
CN101160403B (zh) * 2005-02-18 2014-08-13 安吉奥开米公司 转运化合物穿过血脑屏障的分子
CN100406558C (zh) * 2005-06-14 2008-07-30 吉林圣元科技有限责任公司 制备重组抑酶肽的方法
EP2653542B1 (en) 2005-12-29 2016-06-29 The Regents of The University of California Methods and compositions related to mutant kunitz domain I of TFPI-2
WO2008110301A1 (de) * 2007-03-13 2008-09-18 Bayer Schering Pharma Aktiengesellschaft Aprotinin-varianten mit verbesserten eigenschaften
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
CN116925291A (zh) * 2015-07-31 2023-10-24 罗门哈斯公司 用于合成单峰丙烯酸珠粒的寡聚物晶种

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3309501A1 (de) * 1983-03-17 1984-09-20 Bayer Ag, 5090 Leverkusen Plasmid-vektoren zur klonierung, identifizierung und expression von genen
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
DE3410437A1 (de) * 1984-03-22 1985-09-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von proteinen
ATE64956T1 (de) * 1984-06-14 1991-07-15 Ciba Geigy Ag Verfahren zur herstellung von thrombininhibitoren.
DE3581328D1 (de) * 1984-06-19 1991-02-21 Transgene Sa Derivate des menschlichen alpha-1-antitrypins und verfahren zu deren herstellung.
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
WO1986001229A1 (en) * 1984-08-16 1986-02-27 Bio-Technology General Corp. Method of removing n-terminal amino acid residues from eucaryotic polypetide analogs and polypeptides produced thereby
DE3523701A1 (de) * 1985-07-03 1987-01-08 Bayer Ag Verfahren zur herstellung von proteinen und polypeptiden
GB2188933A (en) * 1986-04-10 1987-10-14 Bayer Ag Expression vectors for production of polypeptides, method for enhanced expression of polypeptides, hosts containing the expression vectors, products manufactured thereby

Also Published As

Publication number Publication date
GB8607523D0 (en) 1986-04-30
JP2537507B2 (ja) 1996-09-25
CN1018793B (zh) 1992-10-28
FI871288A (fi) 1987-09-27
FI871288A0 (fi) 1987-03-24
EP0238993A3 (en) 1989-03-22
IL81964A0 (en) 1987-10-20
DK151687A (da) 1987-09-27
US4894436A (en) 1990-01-16
KR960007194B1 (ko) 1996-05-29
DK151687D0 (da) 1987-03-25
ATE123301T1 (de) 1995-06-15
AU6990187A (en) 1987-10-01
FI94876C (fi) 1995-11-10
EP0238993A2 (de) 1987-09-30
KR950000302B1 (ko) 1995-01-13
FI94876B (fi) 1995-07-31
CN87102412A (zh) 1987-10-07
ZA872181B (en) 1987-12-30
EP0238993B1 (de) 1995-05-31
JPS637794A (ja) 1988-01-13
DE3751324D1 (de) 1995-07-06
KR870009025A (ko) 1987-10-22
AU600475B2 (en) 1990-08-16
ES2073390T3 (es) 1995-08-16
GB2188322A (en) 1987-09-30
CA1338309C (en) 1996-05-07
KR890002401A (ko) 1989-04-10

Similar Documents

Publication Publication Date Title
IL81964A (en) Aprotinin and aprotinin homologues in which the amino acids in positions 15 and 52 have benn substituted
ES2052871T3 (es) Preparacion de bis (3,5-di-t-butil-4-hidroxifeniltio)metano.
MX9805810A (es) Agentes anticoagulantes, utiles en el tratamiento de trombosis.
ES2031806T3 (es) Factor de permeabilidad vascular humano.
EP0236684A3 (en) Galanthamine or analogues thereof for treating alzheimer's disease
WO1995021601A3 (en) Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
ES8702431A1 (es) Procedimiento para preparar una proteina inhibidora de la coagulacion de la sangre
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
ES520340A0 (es) Un procedimiento para la preparacion de diarilpirazinas o triazinas.
DE69005959D1 (de) Verfahren zur Reinigung von menschlichem Serum-Albumin.
FR2491334B1 (fi)
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
ATE90568T1 (de) Verwendung von zink- oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen.
IL96052A0 (en) Method for the prevention and treatment of bovine mastitis
IT8419730A0 (it) Procedimento per la trasformazione quantitativa di teicoplanina a2fattore 1 in teicoplanina a2fattore 3.
NZ229401A (en) Protein extracted from 'hard ticks' having thrombin-inhibitary action
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
DE68900892D1 (de) Zusammenstellung zur behandlung der osteoporose beim menschen.
MX9201825A (es) Composicion farmaceutica que contiene calcitonina.
DE3570677D1 (en) Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation
DE69000960D1 (de) Zusammensetzung zur behandlung von pigmentierung.
IT8840172A0 (it) Procedimento e mezzi per l'impressione in rilievo di tessuti, o pelli e simili
NZ333652A (en) Inhibition of human rotavirus infection using kappa-casein
IT8748573A0 (it) Impiego di magnesite per la modificazione e/o l'espansione di scorie metallurgiche,e relativo procedimento

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees